FGCL-3019-095 Pro00108483 Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Fibrogen, Inc.
Start Date
June 23, 2022
End Date
February 9, 2024
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Fibrogen, Inc.
Start Date
June 23, 2022
End Date
February 9, 2024